Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of OpSCF in the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis

NCT06101823 is registered in ClinicalTrials.gov with Insmed Incorporated as lead sponsor.

NCT NCT06101823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06101823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of OpSCF in the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis
Lead sponsor
Insmed Incorporated
Phase
Phase 2
Overall status
Completed
Start date
November 21, 2023
Completion date
August 18, 2025
Enrollment
50 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis